A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.

Trial Profile

A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs Zoptarelin doxorubicin (Primary) ; Capecitabine; Doxorubicin liposomal; Eribulin; Gemcitabine; Paclitaxel; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors AEterna Zentaris Inc
  • Most Recent Events

    • 14 Jan 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 04 Jun 2013 Study design presented at 49th Annual Meeting of the American Society of Clinical Oncology (ASCO 2013).
    • 01 Jun 2013 Information from this trial will be presented as a poster at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO-2013).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top